The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels

Journal of Neurochemistry

Volumn 105, Issue 4, 2008, Pages 1450-1461

  Buraei, Zafir ^a,b,d   Elmslie, Keith S ^a,c  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Inactivation; Inhibition; R roscovitine; S roscovitine; Slowed deactivation

Indexed keywords

CALCIUM CHANNEL L TYPE; CYCLIN DEPENDENT KINASE; INDIRUBIN 3' MONOXIME; KENPAULLONE; OLOMOUCINE; PHOSPHOTRANSFERASE INHIBITOR; ROSCOVITINE;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG EFFECT; DRUG INACTIVATION; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; IC 50; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; PURINES; RANA CATESBEIANA; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS PROTEINS;

EID: 42549172301     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05248.x     Document Type: Article

References (52)

1. Bean B. P. (1984) Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc. Natl Acad. Sci. USA 81, 6388 6392.
2. Belevych A. E., Warrier S. Harvey R. D. (2002) Genistein Inhibits Cardiac L-Type Ca2+ Channel Activity by a Tyrosine Kinase-Independent Mechanism. Mol. Pharmacol. 62, 554 565.
3. Binarova P., Dolezel J., Draber P., Heberle-Bors E., Strnad M. Bogre L. (1998) Treatment of Vicia faba root tip cells with specific inhibitors to cyclin-dependent kinases leads to abnormal spindle formation. Plant J. 16, 697 707.
4. Blagden S. de Bono J. (2005) Drugging cell cycle kinases in cancer therapy. Curr. Drug Targets 6, 325 335.
5. Boland L. M., Morrill J. A. Bean B. P. (1994) omega-Conotoxin block of N-type calcium channels in frog and rat sympathetic neurons. J. Neurosci. 14, 5011 5027.
6. Buraei Z., Anghelescu M. Elmslie K. S. (2005a) Slowed N-Type Calcium Channel (CaV2.2) Deactivation by the Cyclin-Dependent Kinase Inhibitor Roscovitine. Biophys. J. 89, 1681 1691.
7. Buraei Z., Schofield G. Elmslie K. S. (2005b) Roscovitine specifically slows deactivation of CaV2 (P/Q-, N-, and R.-Type) channels to enhance action potential-induced Ca2+ influx. Program No. 265.3. 2005 Abstract Viewer/Itinerary Planner. Soc. Neuroscience, Washington DC.
8. Buraei Z., Schofield G. Elmslie K. S. (2007) Roscovitine differentially affects CaV2 and Kv channels by binding to the open state. Neuropharmacology 52, 883 894.
9. Cho S. Meriney S. D. (2006) The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur. J. Neurosci. 23, 3200 3208.
10. Cox D. H. Dunlap K. (1994) Inactivation of N-type calcium current in chick sensory neurons: calcium and voltage dependence. J. Gen. Physiol. 104, 311 336.
11. de Azevedo W. F., Leclerc S., Meijer L., Havlicek L., Strnad M. Kim S. H. (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518 526.
12. Degtiar V. E., Scheller R. H. Tsien R. W. (2000) Syntaxin modulation of slow inactivation of N-type calcium channels. J. Neurosci. 20, 4355 4367.
13. Elmslie K. S. (2004) Calcium channel blockers in the treatment of disease. J. Neurosci. Res. 75, 733 741.
14. Elmslie K. S., Kammermeier P. J. Jones S. W. (1992) Calcium current modulation in frog sympathetic neurones: L-current is relatively insensitive to neurotransmitters. J. Physiol. 456, 107 123.
15. Elmslie K. S., Kammermeier P. J. Jones S. W. (1994) Reevaluation of Ca2+ channel types and their modulation in bullfrog sympathetic neurons. Neuron 13, 217 228.
16. Elmslie K. S., Zhou W. Jones S. W. (1990) LHRH and GTP-gamma-S modify calcium current activation in bullfrog sympathetic neurons. Neuron 5, 75 80.
17. Fitzgerald E. M. (2000) Regulation of voltage-dependent calcium channels in rat sensory neurones involves a Ras-mitogen-activated protein kinase pathway. J. Physiol. 527 (Pt 3 433 444.
18. Frace A. M., Mery P. F., Fischmeister R. Hartzell H. C. (1993) Rate-limiting steps in the beta-adrenergic stimulation of cardiac calcium current. J Gen Physiol. 101, 337 353.
19. Franckowiak G., Bechem M., Schramm M. Thomas G. (1985) The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels. Eur. J. Pharmacol. 114, 223 226.
20. Gray W. M. (2004) Hormonal regulation of plant growth and development. PLoS Biol. 2, E311.
21. Hahntow I. N., Schneller F., Oelsner M., Weick K., Ringshausen I., Fend F., Peschel C. Decker T. (2004) Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18, 747 755.
22. Hartzell H. C., Mery P. F., Fischmeister R. Szabo G. (1991) Sympathetic regulation of cardiac calcium current is due exclusively to cAMP-dependent phosphorylation. Nature 351, 573 576.
23. Havlicek L., Hanus J., Vesely J., Leclerc S., Meijer L., Shaw G. Strnad M. (1997) Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40, 408 412.
24. Hoessel R., Leclerc S., Endicott J. A., et al. (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1, 60 67.
25. Iseki H., Ko T. C., Xue X. Y., Seapan A., Hellmich M. R. Townsend Jr. C. M. (1997) Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery 122, 187 194 discussion 194 185.
26. Iseki H., Ko T. C., Xue X. Y., Seapan A. Townsend Jr. C. M. (1998) A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. J. Gastrointest. Surg. 2, 36 43.
27. Jahnsen H. Llinas R. (1984) Electrophysiological properties of guinea-pig thalamic neurones: an in vitro study. J. Physiol. 349, 205 226.
28. Jones S. W. (1989) On the resting potential of isolated frog sympathetic neurons. Neuron 3, 153 161.
29. Kaye D. M. Krum H. (2007) Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov. 6, 127 139.
30. Klemic K. G., Kirsch G. E. Jones S. W. (2001) U-type inactivation of Kv3.1 and Shaker potassium channels. Biophys J. 81, 814 826.
31. Krystof V., Lenobel R., Havlicek L., Kuzma M. Strnad M. (2002) Synthesis and biological activity of olomoucine II. Bioorg. Med. Chem. Lett. 12, 3283 3286.
32. Lee H. R., Chang T. H., Tebalt III. M. J., Senderowicz A. M. Szabo E. (1999) Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. Int. J. Oncol. 15, 161 166.
33. Leost M., Schultz C., Link A., et al. (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267, 5983 5994.
34. Liang H. Elmslie K. S. (2001) E(f)-current contributes to whole-cell calcium current in low calcium in frog sympathetic neurons. J. Neurophysiol. 86, 1156 1163.
35. Lin Y., McDonough S. I. Lipscombe D. (2004) Alternative Splicing in the Voltage-Sensing Region of N-Type CaV2.2 Channels Modulates Channel Kinetics. J. Neurophysiol. 92, 2820 2830.
36. Lymperopoulos A., Rengo G., Funakoshi H., Eckhart A. D. Koch W. J. (2007) Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13, 315 323.
37. McClue S. J., Blake D., Clarke R., et al. (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463 468.
38. Meijer L. (1996) Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol., 6, 393 397.
39. Meijer L., Borgne A., Mulner O., Chong J., Blow J., Inagaki N., Inagaki M., Delcros J. Moulinoux J. (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527 536.
40. Mesecar A. D. Koshland Jr. D. E. (2000) A new model for protein stereospecificity. Nature 403, 614 615.
41. Mgbonyebi O. P., Russo J. Russo I. H. (1998) Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Res. 18, 751 755.
42. Mihara M., Shintani S., Kiyota A., Matsumura T. Wong D. T. (2002) Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int. J. Oncol. 21, 95 101.
43. Monaco III. E. A. Vallano M. L. (2005) Roscovitine triggers excitotoxicity in cultured granule neurons by enhancing glutamate release. Mol Pharmacol. 68, 1331 1342.
44. Sanguinetti M. C. Kass R. S. (1984) Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists. Circ. Res. 55, 336 348.
45. Smith D. S., Greer P. L. Tsai L. H. (2001) Cdk5 on the brain. Cell Growth Differ. 12, 277 283.
46. Tomizawa K., Ohta J., Matsushita M., Moriwaki A., Li S.-T., Takei K. Matsui H. (2002) Cdk5/p35 Regulates Neurotransmitter Release through Phosphorylation and Downregulation of P/Q-Type Voltage-Dependent Calcium Channel Activity. J. Neurosci. 22, 2590 2597.
47. Triggle D. J. (2003) Drug targets in the voltage-gated calcium channel family: why some are and some are not. Assay Drug Dev. Technol. 1, 719 733.
48. Vesely J., Havlicek L., Strnad M., et al. (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 224, 771 786.
49. Walker J., Minshall N., Hake L., Richter J. Standart N. (1999) The clam 3′ UTR masking element-binding protein p82 is a member of the CPEB family. RNA 5, 14 26.
50. Wesierska-Gadek J., Gueorguieva M. Horky M. (2005) Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol. Cancer Ther. 4, 113 124.
51. Yan Z., Chi P., Bibb J. A., Ryan T. A. Greengard P. (2002) Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J. Physiol. (Lond) 540, 761 770.
52. Yarotskyy V. Elmslie K. S. (2007) Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. Br. J. Pharmacol. 152, 386 395.